These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 26686791)

  • 1. Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study.
    Gagne JJ; Najafzadeh M; Choudhry NK; Bykov K; Kahler KH; Martin D; Rogers JR; Schneeweiss S
    Value Health; 2015 Dec; 18(8):1057-62. PubMed ID: 26686791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data.
    Gagne JJ; Bykov K; Najafzadeh M; Choudhry NK; Martin DP; Kahler KH; Rogers JR; Schneeweiss S
    Value Health; 2015 Dec; 18(8):1063-9. PubMed ID: 26686792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unified framework for classification of methods for benefit-risk assessment.
    Najafzadeh M; Schneeweiss S; Choudhry N; Bykov K; Kahler KH; Martin DP; Gagne JJ
    Value Health; 2015 Mar; 18(2):250-9. PubMed ID: 25773560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.
    Lynd LD; Najafzadeh M; Colley L; Byrne MF; Willan AR; Sculpher MJ; Johnson FR; Hauber AB
    Value Health; 2010; 13(4):411-7. PubMed ID: 19744297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.
    Guo JJ; Pandey S; Doyle J; Bian B; Lis Y; Raisch DW
    Value Health; 2010 Aug; 13(5):657-66. PubMed ID: 20412543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies.
    Crespo C; Monleon A; Díaz W; Ríos M
    BMC Med Res Methodol; 2014 Dec; 14():139. PubMed ID: 25533141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing alerting thresholds for prospective drug safety monitoring.
    Wangge G; Schneeweiss S; Glynn RJ; Gagne JJ
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):755-62. PubMed ID: 26596260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment.
    Towse A
    Value Health; 2010 Jun; 13 Suppl 1():S30-2. PubMed ID: 20618793
    [No Abstract]   [Full Text] [Related]  

  • 9. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.
    Gagne JJ; Wang SV; Rassen JA; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):619-27. PubMed ID: 24788694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality-of-life-adjusted hazard of death: a formulation of the quality-adjusted life-years model of use in benefit-risk assessment.
    Garcia-Hernandez A
    Value Health; 2014 Mar; 17(2):275-9. PubMed ID: 24636387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
    Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of number needed to treat in cost-effectiveness analyses.
    Garg V; Shen X; Cheng Y; Nawarskas JJ; Raisch DW
    Ann Pharmacother; 2013 Mar; 47(3):380-7. PubMed ID: 23463742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the congestion charging scheme on air quality in London. Part 1. Emissions modeling and analysis of air pollution measurements.
    Kelly F; Anderson HR; Armstrong B; Atkinson R; Barratt B; Beevers S; Derwent D; Green D; Mudway I; Wilkinson P;
    Res Rep Health Eff Inst; 2011 Apr; (155):5-71. PubMed ID: 21830496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative effectiveness assessment of listed drugs (REAL): a new method for an early comparison of the effectiveness of approved health technologies.
    Falissard B; Izard V; Xerri B; Bouvenot G; Meyer F; Degos L
    Int J Technol Assess Health Care; 2010 Jan; 26(1):124-30. PubMed ID: 20059790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research.
    Gagne JJ; Bykov K; Willke RJ; Kahler KH; Subedi P; Schneeweiss S
    Value Health; 2013; 16(6):1054-62. PubMed ID: 24041355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the safety of amiodarone.
    Santangeli P; Di Biase L; Burkhardt JD; Bai R; Mohanty P; Pump A; Natale A
    Expert Opin Drug Saf; 2012 Mar; 11(2):191-214. PubMed ID: 22324910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.